February 28, 2017 12:49 AM ET

Pharmaceuticals

Company Overview of Intersect ENT, Inc.

Company Overview

Intersect ENT, Inc., a commercial stage drug-device company, provides therapeutic solutions for patients with ear, nose, and throat conditions in the United States. It offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis. The company is also developing RESOLVE, a steroid releasing implant for refractory disease for the treatment of patients in the physician office setting; and NOVA, a steroid releasing implant to fit the ostia, or openings, of the dependent sinuses following enlargement of the sinuses. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, I...

1555 Adams Drive

Menlo Park, CA 94025

United States

Founded in 2003

275 Employees

Phone:

650-641-2100

Key Executives for Intersect ENT, Inc.

Chief Executive Officer, President and Director
Age: 46
Total Annual Compensation: $442.4K
Chief Financial Officer
Age: 58
Total Annual Compensation: $357.9K
Chief Operating Officer and Vice President of R&D & Operations
Age: 54
Total Annual Compensation: $324.1K
Vice President of Clinical Affairs
Age: 46
Total Annual Compensation: $263.7K
Compensation as of Fiscal Year 2015.

Intersect ENT, Inc. Key Developments

Intersect ENT, Inc. Maintains Revenue Guidance for the Year 2017

Intersect ENT, Inc. company maintained its previously stated 2017 revenue guidance of $87 million to $89 million.

Intersect ENT, Inc. Wins FDA Approval of Newest Steroid Releasing Implant, PROPEL Contour, for Use in Treating the Frontal and Maxillary Sinuses

Intersect ENT, Inc. announced that the company has received approval from the U.S. Food and Drug Administration (FDA) for its PROPEL® Contour steroid releasing sinus implant. PROPEL Contour features an innovative hourglass design that facilitates treatment of patients with chronic sinusitis in the frontal (behind the forehead) and maxillary (behind the cheeks) sinuses. With this approval, Intersect ENT's PROPEL family of steroid releasing implants allows for treatment of patients undergoing ethmoid, frontal or maxillary surgeries, which represent the majority of procedures for the treatment of chronic sinusitis. PROPEL Contour, the latest in the PROPEL family of steroid releasing sinus implants, is specifically designed to conform to the sinus ostia (openings), focusing drug delivery and mechanical support where it is needed in order to maximize sinus surgery outcomes. The implant features a low-profile flexible delivery system to make it easier to access tight areas of the sinus anatomy. Positive data from the PROPEL Contour cohort of the PROGRESS study, a prospective, randomized, blinded, multi-center trial of 80 patients designed to assess the safety and efficacy of the implant when placed in the frontal sinuses following surgery, supported the approval. The study met its primary efficacy endpoint, demonstrating a statistically significant 65% relative reduction in the need for post-operative interventions, such as the need for additional surgical procedures or the need for oral steroid prescription, compared to surgery alone.

Intersect ENT, Inc. Presents at The Leerink Partners 6th Annual Global Healthcare Conference, Feb-16-2017 10:30 AM

Intersect ENT, Inc. Presents at The Leerink Partners 6th Annual Global Healthcare Conference, Feb-16-2017 10:30 AM. Venue: Lotte New York Palace, 455 Madison Ave., New York, New York, United States.

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Intersect ENT, Inc., please visit www.intersectent.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.